Valeant Pharma (NYSE: VRX) issued a response to allegations by Bronte Capital, saying:Short sellers have been making false, unsubstantiated claims ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE